Recruiting clinical trials in CH

AMG 510 (sotorasib)

Covalent KRASG12C inhibitor
Phase Ib/II
Combination
none (only outside of CH)
Indication
Tumor agnostic
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)
Amgen protocol ID 20170543
Status Switzerland
Phase 2 recruiting (adv. solid tumors)
(NSCLC & CRC cohorts full)
Centers, Principal Investigators (PI):
USB, S. Rothschild
USZ, A. Curioni
HUG, A. Addeo
AMG 510 (sotorasib)

Covalent KRASG12C inhibitor
Phase III
Combination
none
Indication
NSCLC
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 (sotorasib) Versus Docetaxel for the treatment of Previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C. (CodeBreak 200)
Amgen protocol ID 20190009
Status Switzerland
Screening/Recruiting
Centers, PI:
KSW, M. Pless
USZ, A. Curioni
Inselspital, S. Häfliger
HUG, A. Addeo
CHUV, S. Peters
USB, S. Rothschild
AMG 757

DLL3 x CD3 Half-life extended Bispecific T-Cell Engager
Phase I
Combination
+/- Pembrolizumab
Indication
SCLC
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
Amgen protocol ID 20160323
Status Switzerland
Recruitment to start in September 2020
Centers, PI:
CHUV, S. Peters
T-VEC

Oncolytic Virus
Phase I/II
Combination
+ Pembrolizumab
Indication
BrCa (ER+, TNBC), CRC, HCC, BCC, CSCC
A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318)
Amgen protocol ID 20140318
Status Switzerland
Phase 1: Recruiting HCC
Phase 2: Recruiting
Centers, PI:
KSW, M. Pless
USZ, R. Fritsch
CHUV, A. Digklia
HUG, N. Mach
T-VEC

Oncolytic Virus
Phase I
Combination
none
Indication
Pediatric
A Phase 1, Multicenter, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Amgen protocol ID 20110261
Status Switzerland
Recruiting
Centers, PI:
Universitäts-Kinderspital Zürich, N. Gerber
USB, T. Kühne

For further questions relating to the study programme, please contact Carine Bast or Eva Vollenweider

Nutzungsbedingungen:
Die medizinisch-wissenschaftlichen Informationen auf dieser Website science.amgen.ch sind ausschliesslich für medizinisches Fachpersonal aus der Schweiz bestimmt.

Ich bin kein Angehörige(r) des medizinischen Fachpersonals aus der Schweiz.